ArticleJoint diseases and related surgery2025
The role of high large unstained cell percentages in ongoing inflammation in the intercritical gout.
Article in Joint diseases and related surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biosafety assessment of engineered CCL20 locked dimers in vivo.Cell biology and toxicology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aims to investigate whether large unstained cells (LUCs) is a marker of inflammation in gout patients and whether it is associated with different clinical conditions such as erosion, tophus, intercritical period, and gout flare. PATIENTS AND
methodsBetween November 2022 and May 2023, a total of 100 consecutive adult gout patients (81 males, 19 females; mean age 53.8±12.8 years; range, 21 to 79 years) and 30 healthy controls (24 males, 6 females; mean age 57.2±10.6 years; range, 28 to 75) were included in this cross-sectional study. Data including demographics, clinical characteristics, laboratory results and direct radiography images of affected joints at the most recent visit were recorded.
resultsLeukocyte counts were found to be significantly higher in gout patients (p=0.048). The LUC counts and percentages and levels of acute phase reactants were similar between the patient and control groups (p=0.401, p=0.668, p=0.222, and p=0.505, respectively). In subgroup analyses of the gout patients, there were no significant differences in LUC counts and percentages between those with tophaceous disease (p=0.650 and p=0.388, respectively), erosions (p=0.154 and p=0.137, respectively) and elevated serum uric acid levels (p=0.918 and p=0.196, respectively). However, LUC percentages were statistically significantly higher in patients without elevated C-reactive protein (CRP) and in the intercritical gout (p=0.039 and p=0.05, respectively).
conclusionOur study results showed similar LUC counts and percentages between the gout patients and healthy controls. However, in the subgroup analysis of the gout patients, the LUC percentages were observed to be significantly higher in those without high CRP levels and in patients with intercritical gout. This finding may suggest that subclinical inflammation persists in intercritical gout.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.